valu usd unless otherwis note
sentiment guidanc valuat low like
tactic set-up upgrad op
view conjunct move bullish sector view
cyclic improv ahead revisit struggl us
get behind name varieti reason recent sizabl cut
guidanc neg sentiment near street-low valuat make
entri point allur particularli set near-term gener
advair/restasi approv rais target
first time sinc aug outperform
rate stock unabl retrac back level sinc
think set chang host hesit upgrad
stock includ fragil us base busi
slow call ii serial bolt-on deal often disclos file make
difficult ascertain underli organ growth iii frustrat around
capit deploy decis buy ep via share repurchas
higher level instead reduc leverag word still
concern view tactic stock
inexpens think number bottom neg sentiment
improv near-term catalyst three driver thesi
number rebas growth ramp come
magnitud guidanc cut set realist floor
acceler growth new ebitda
billion billion billion billion reflect
steadi growth lower base includ next year
street-low head come still low end guidanc
year ev/ebitda newli rebas number
hard anticip upward move
ii near-term pipelin add support us gener base
materi smaller pruning/restructur complex pipelin
acceler growth smaller base gener advair
restasi could near-term approv push
contribut model hangup us
concern around over-model complex product opportun
ignor increasingli aggress brand rebat tactic aggress
rebat new author gener made clear
view econom captur chang import us
iii upsid notabl financi flexibl set improv trough
price-to-earnings support upsid case announc strateg review
unlik go anywher commit act timelin given
leverag integr platform sure review
strategi review ordinari cours board commit
pay billion debt next year net leverag
push end potenti gener up-cycl
price prior trade day market close estimate unless otherwis note
view well posit long-term pipelin
diversifi revenu base learn
last year immun gener industri
pressur manag late capitul react
led steadi downward earn revis
think bottom stronger remain core base
combin emerg complex gener pipelin
posit share upward move follow primari
driver outperform thesi stock
face mani sector headwind
pressur peer given diversif activ
reposit think set see growth improv
come year
sever import pipelin catalyst
drive support improv sentiment
long-term growth outlook still appear stabl
increasingli diversifi global footprint import
addit potenti competit epipen gener
copaxon see lower growth peer
risk view three risk view
delay around pipelin convers specif gener
advair restasi ii impair us base
busi view weaker appreci
risk step-down ebitda contribut
inopportun use cash boost leverag perpetu
upcom potenti catalyst event focu
gener restasi approv juli bridg goal date
pass gener advair potenti quick
approv turnaround addit accret use
capit debt paydown
bloomberg capit market estim upside/downside/target
base case scenario see stock price impli
price-to-earnings ep ev/ebitda
steadi new gener approv activ low teen us
gener eros base busi
pipelin approv gener restasi gener
advair risk adjust
addit accret though assum
addit debt pay buyback outer year
upsid scenario see valu impli price-to-earnings
upsid ep
inflect higher gener approv activ continu
accret supplement organ growth
portfolio addit debt paydown buyback outer
limit competit high-valu gener greater-
downsid scenario see valu impli price-to-earnings
ep
greater price pressur across us gener portfolio
lead gross margin depress
slowdown ou fail off-set pressur us
failur maintain steadi pipelin convers off-set
exhibit
 incom guid mid teen declin north guid hsd growth eurest guid hsd growth rowoth gener total revenu guid bncost gross profit guid guid total revenuessg guid total revenuesoper incom incom incom tax incom guid incom prefer dividend adjust net guid billionep adjust guid dilut share guid million guid billion growth ebitda analysi margin guid guid total guid total revenuesoper expens guid net incom pharmaceuticals/specialti
price target base equal price-to-earnings ev/ebitda use target
multipl result gener valuat framework
taken trough price-to-earnings valuat histor averag valuat made adjust
base compani specif attribut attribut result adjust
lower impli return price target support outperform rate
risk rate price target
risk rate price target includ limit earlier-than-expect
approv key product advair extend delay accret drive
favor accret addit pipelin surpris
lead global gener manufactur base pittsburgh pennsylvania employ
peopl global compani found transform
last sever year notabl acquisit merck kgaa
compani benefit differ revenu sourc help grow
eu auster headwind us comp strength recent year
